Insys Therapeutics, a pharmaceutical company and major financial opponent to marijuana legalization in Arizona last year, has received preliminary approval from the Drug Enforcement Administration to offer Syndros, a synthetic marijuana drug.
The Chicago Tribune reports that Insys gave $500,000 last summer to Arizonans for Responsible Drug Policy, the group opposing marijuana legalization in Arizona. The opposition worked and the measure was defeated. The Washington Post showed that Insys was the only pharmaceutical company that could be proven to be giving money to oppose marijuana legalization in 2016.
The company that blocked legal weed in Arizona just got approved for a synthetic marijuana drug.
Posted by ATTN: Video on Monday, March 27, 2017
Syndros is a synthetic form of THC, the main psychoactive in cannabis. It was approved by the FDA last summer to treat nausea, vomiting and weight loss in cancer and AIDS patients. Those are among conditions that REAL cannabis has been proven to provide relief.
Insys has been involved in chicanery for several years. In 2011 the company wrote to the DEA opposing any lessening in restrictions on THC, citing “abuse potential.” Then, in 2016 it again petitioned the DEA to loosen restrictions on synthetic CBD. CBD is the non-psychoactive compound in cannabis has already been proven to help medical patients, especially children.
But Insys doesn’t want the naturally grown marijuana compound to help children, instead, it wants to market a synthetic version of a CBD-based drug for use in treating pediatric epilepsy.
The company was subjected to criminal investigations and a shareholder lawsuit over what the Chicago Tribune called “aggressive marketing of a product containing the potent and deadly opioid painkiller fentanyl.” Last December, the FBI arrested the company’s former chief executive and five other executives on charges that they “paid kickbacks and committed fraud to sell a highly potent and addictive opioid that can lead to abuse and life-threatening respiratory depression.”
Interestingly, Insys is now developing a drug to treat opioid overdose. That is to treat overdoses from narcotics whose use could have been lessened by legal marijuana, which Insys opposed.